IL174525A0 - Medicamentously targeted local lipolysis - Google Patents

Medicamentously targeted local lipolysis

Info

Publication number
IL174525A0
IL174525A0 IL174525A IL17452506A IL174525A0 IL 174525 A0 IL174525 A0 IL 174525A0 IL 174525 A IL174525 A IL 174525A IL 17452506 A IL17452506 A IL 17452506A IL 174525 A0 IL174525 A0 IL 174525A0
Authority
IL
Israel
Prior art keywords
medicamentously
targeted local
local lipolysis
lipolysis
adipose tissue
Prior art date
Application number
IL174525A
Original Assignee
Merz Pharmaceuticals Gmbh
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL174525(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharmaceuticals Gmbh, Sanofi Aventis Deutschland filed Critical Merz Pharmaceuticals Gmbh
Publication of IL174525A0 publication Critical patent/IL174525A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to aqueous phospholipid systems, containing at least one phospholipid, at least one bile acid and water, which are suitable for producing medicaments for the treatment of adipose tissue diseases and which lead to the regression of the diseased proliferated adipose tissue.
IL174525A 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis IL174525A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979A DE10349979B4 (en) 2003-10-24 2003-10-24 Drug targeted local lipolysis
PCT/EP2004/011320 WO2005041919A2 (en) 2003-10-24 2004-10-09 Medicamentously targeted local lipolysis

Publications (1)

Publication Number Publication Date
IL174525A0 true IL174525A0 (en) 2006-08-01

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174525A IL174525A0 (en) 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis

Country Status (14)

Country Link
EP (1) EP1684722B1 (en)
JP (1) JP2007509085A (en)
KR (1) KR20060117914A (en)
CN (1) CN100482211C (en)
AT (1) ATE418965T1 (en)
AU (1) AU2004285264A1 (en)
BR (1) BRPI0415756A (en)
CA (1) CA2543187A1 (en)
DE (2) DE10349979B4 (en)
ES (1) ES2319997T3 (en)
HK (1) HK1096857A1 (en)
IL (1) IL174525A0 (en)
MX (1) MXPA06004081A (en)
WO (1) WO2005041919A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (en) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of fat accumulations
ATE521355T1 (en) * 2004-05-19 2011-09-15 Los Angeles Biomed Res Inst USE OF A DETERGENT FOR NON-SURGICAL FAT REMOVAL
DE102007015701A1 (en) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh New pharmaceutical compositions for lipolysis and process for their preparation
KR101623780B1 (en) 2009-08-25 2016-05-24 가부시키가이샤 메드렉스 Transdermal composition of phosphatidylcholine and method for producing same
DE102010028365A1 (en) * 2010-04-29 2011-11-03 Lichtblick Gmbh Use of a phospholipid-containing composition for the removal of subcutaneous fat accumulations
KR101353443B1 (en) * 2012-02-07 2014-01-29 주식회사 아미팜 Injectable composition of phosphatidylcholine devoid of sodium deoxycholate and manufacturing method thereof
RU2682249C2 (en) * 2012-05-31 2019-03-18 Терумо Кабусики Кайся Ph-sensitive carrier and method for production thereof, ph-sensitive medicine and ph-sensitive pharmaceutical composition each containing said carrier, and culture method using said ph-sensitive medicine or said ph-sensitive pharmaceutical composition
NZ727407A (en) * 2014-06-27 2018-12-21 Medytox Inc Methods and compositions of bile acids and salts for reduction of fat
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
ES2949946T3 (en) * 2017-04-21 2023-10-04 Ami Pharm Co Ltd Injectable composition for localized fat reduction without pain, edema or side effects, and method for preparing it
KR101865562B1 (en) * 2017-11-03 2018-06-08 주식회사 펜믹스 Lipolytic composition containing phosphocholine derivatives
EP3646874B1 (en) 2018-01-31 2024-01-24 Unish Inc. Phosphatidylcholine transdermal absorption preparation
KR20190095833A (en) * 2018-02-07 2019-08-16 이기택 Phosphatidylcholine-free injectable composition for localized fat reduction without pain and side effect
WO2019203543A1 (en) * 2018-04-18 2019-10-24 (주)인벤티지랩 Composition for subcutaneous injection, containing deoxycholic acid, and preparation method therefor
WO2021246301A1 (en) 2020-06-01 2021-12-09 コスメディ製薬株式会社 Beauty microneedle array

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (en) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Medicinal preparations based on oily solutions of phospholipids
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
DE4122744C2 (en) * 1990-08-06 1994-02-03 Nattermann A & Cie Aqueous liposome system and process for its preparation
DE4308121A1 (en) * 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Aqueous liposome system and method for producing such a liposome system
ITMI20011182A1 (en) * 2001-06-05 2002-12-05 Indena Spa PHARMACEUTICAL AND / OR COSMETIC COMPOSITIONS FOR THE TREATMENT OF LOCALIZED ADIPOSITIES AND CELLULITE

Also Published As

Publication number Publication date
JP2007509085A (en) 2007-04-12
BRPI0415756A (en) 2006-12-19
ES2319997T3 (en) 2009-05-18
CA2543187A1 (en) 2005-05-12
DE10349979A1 (en) 2005-06-16
ATE418965T1 (en) 2009-01-15
MXPA06004081A (en) 2006-06-27
EP1684722A2 (en) 2006-08-02
KR20060117914A (en) 2006-11-17
EP1684722B1 (en) 2008-12-31
DE502004008793D1 (en) 2009-02-12
AU2004285264A1 (en) 2005-05-12
WO2005041919A3 (en) 2005-06-23
DE10349979B4 (en) 2006-05-18
CN1870977A (en) 2006-11-29
HK1096857A1 (en) 2007-06-15
WO2005041919A2 (en) 2005-05-12
CN100482211C (en) 2009-04-29

Similar Documents

Publication Publication Date Title
IL174525A0 (en) Medicamentously targeted local lipolysis
DE502005010615D1 (en) MEDICINE FOR THE TREATMENT OF INFLAMMATORY DISEASES
TW201712023A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
NO20081527L (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EA200971053A1 (en) METHODS OF TREATMENT OF THE LEAD ULCERS
NZ709704A (en) Protein formulations and methods of making same
CL2011003346A1 (en) Compounds derived from 2,3-dihydro-5h- [1,3] thiazolo [3,2-a] pyrimidin-5-one, modulators of pi3k; pharmaceutical composition; and use to treat an immune-based disease, cancer, or lung disease in a patient.
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
DE60328476D1 (en) MEDICAL BALLOON SYSTEM FOR THE TREATMENT OF ADIPOSITAS
DE50310516D1 (en) Fredericamycin DERIVATIVES
DE602005026866D1 (en) USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
WO2007136679A3 (en) Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
DE60320007D1 (en) PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
NO20053077D0 (en) Therapeutic formulations for the treatment of beta-amyloid-related diseases.
ATE316077T1 (en) PYRIMIDINE ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF CRTH2-RELATED DISEASES
GB0222495D0 (en) Compounds
MXPA05012061A (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity.
TW200611695A (en) Pyrrolopyridine derivatives
CR20240003A (en) Novel therapeutic delivery moieties and uses thereof
EA201891507A1 (en) ACID ALPHA-GLUCOSIDASE OF STRENGTHENING ACTION FOR THE TREATMENT OF POMPE DISEASE
CY1116938T1 (en) HUNTINGTON AND OTHER POLYGLUTAMINE DISEASE REFUNDS
IL186707A (en) Mitotic kinesin inhibitors and pharmaceutical compostions comprising them
MXPA04004306A (en) Use of endothelin receptor antagonists in the treatment of tumour diseases.
MXPA05003818A (en) Gene expression profiling from ffpe samples.
MX2009005550A (en) Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy.